Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

E. Vichinsky, R. Fischer, Z. Pakbaz, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B.U. Mueller, L. Coïc, G. Forni, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, I. Gathmann, D. Alberti, P. Marks

Blood (2005) 106 (11): 2334.

https://doi.org/10.1182/blood.V106.11.2334.2334

Published: 2005

Journal Articles

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Is Effective in Reducing Iron Overload in Patients with Advanced Fibrosis and Cirrhosis.

E. Angelucci, B. Turlin, D. Canatan, A. Mangiagli, V. De Sanctis, B. Meddeb, C. Rose, D. Soulieres, M. Cunningham, N. Gattermann, C. Ressayre-Djaffer, B. Rabault, J. Ford

Blood (2005) 106 (11): 2696.

https://doi.org/10.1182/blood.V106.11.2696.2696

Published: 2005

Journal Articles

Patient Satisfaction with Deferasirox (Exjade ® , ICL670) an Oral Form of Chelation Therapy Versus Deferoxamine an Infused Chelation Therapy.

M.D. Cappellini, M. Bejaoui, L. Agaoglu, M.E. Lai, A. Mangiagli, G. Strauss, R. Girot, H. Opitz, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, J. Ford

Blood (2005) 106 (11): 2704.

https://doi.org/10.1182/blood.V106.11.2704.2704

Published: 2005

Journal Articles

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

E. Vichinsky, R. Fischer, E. Fung, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B. U. Mueller, F. Bernaudin, G. L. Forni, C. Ressayre-Djaffer, I. Gathmann, J. Holland, D. Alberti, P. Marks

Blood (2005) 106 (11): 313.

https://doi.org/10.1182/blood.V106.11.313.313

Published: 2005

Journal Articles

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.

P. Brissot, B. Turlin, G.L. Forni, G. Alimena, G. Quarta, D. Selleslag, A. Thompson, F. Locatelli, A. Berretta, M. de Montalembert, C. Ressayre-Djaffer, B. Rabault, J. Ford, D. Alberti

Blood (2005) 106 (11): 823.

https://doi.org/10.1182/blood.V106.11.823.823

Published: 2005

NARROW

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Is Effective in Reducing Iron Overload in Patients with Advanced Fibrosis and Cirrhosis.

Patient Satisfaction with Deferasirox (Exjade ® , ICL670) an Oral Form of Chelation Therapy Versus Deferoxamine an Infused Chelation Therapy.

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.

Email alerts

ASH Publications

American Society of Hematology

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Is Effective in Reducing Iron Overload in Patients with Advanced Fibrosis and Cirrhosis.

Patient Satisfaction with Deferasirox (Exjade ® , ICL670) an Oral Form of Chelation Therapy Versus Deferoxamine an Infused Chelation Therapy.

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only